Adial Pharmaceuticals, Inc. $ADIL

By Microcap Ledger desk · CIK 0001513525

Facts as of Oct 11, 2026, 06:11 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

This page is still filling in. We publish more sections as filings are processed.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Charlottesville, VA
Fiscal year end: December 31
Shares outstanding: 2,625,890 [10-Q 2026-08-14]
as of 2026-08-12

Sources: [10-K 2026-03-05]

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$54.01M	−$7.97M	$28.71M	[10-Q 2026-08-14]
FY ended Dec 2025	—	−$7978.00B	−$6.49M	$5.88M	[DEF 14A 2026-08-24]
FY ended Dec 2024	—	−$13197.00B	−$6.92M	$3.75M	[DEF 14A 2026-08-24]

Quarterly cash burn: −$3.99M
Cash runway Estimate: ~21.6 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-12	6,405,781	[10-Q 2024-11-13]
2025-02-28	6,574,588	[10-K 2025-03-04]
2025-05-13	7,900,695	[10-Q 2025-05-14]
2025-08-08	21,828,215	[10-Q 2025-08-13]
2025-11-07	23,987,587	[10-Q 2025-11-13]
2026-03-04	1,427,970	[10-K 2026-03-05]
2026-05-06	2,143,621	[10-Q 2026-05-08]
2026-08-12	2,625,890	[10-Q 2026-08-14]

Shelf registration: S-3 filed 2026-08-28; no effectiveness notice found in EDGAR [S-3 2026-08-28]

Listing status

Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-08-21	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-08-21]
2025-09-03	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-09-03]
2025-05-30	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-05-30]
2025-03-07	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-03-07]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-07-16	Coastlands Capital Lp	buy	1,233	$2.75	[4 2026-07-16]
2026-07-14	Coastlands Capital Lp	buy	2,000	$2.65	[4 2026-07-16]
2026-07-10	Coastlands Capital Lp	buy	1,700	$2.70	[4 2026-07-13]
2026-07-09	Coastlands Capital Lp	buy	10,053	$2.79	[4 2026-07-13]
2026-06-29	Coastlands Capital Lp	buy	25,000	$2.60	[4 2026-07-01]
2026-06-12	Davidson Matt	grant	232,417	—	[4 2026-06-16]
2026-06-11	Davidson Matt	grant	61,647	—	[4 2026-06-16]
2026-06-11	Davidson Matt	grant	3,427	—	[4 2026-06-16]
2026-06-11	Davidson Matt	grant	1,822.13	—	[4 2026-06-16]
2026-06-11	Davidson Matt	grant	101.298	—	[4 2026-06-16]
2026-04-07	Goodman Tony	grant	26,510	—	[4 2026-04-09]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-02	8-K	Other events
2026-09-18	8-K	Director or officer change; Shareholder vote results
2026-09-16	8-K	Material agreement entered; Other events
2026-08-28	S-3	Registration statement
2026-08-25	8-K	Unregistered sale of equity
2026-08-24	DEF 14A	Proxy statement
2026-08-21	8-K	Listing notice or transfer
2026-08-17	8-K	Results of operations
2026-08-14	10-Q	Quarterly report
2026-08-13	8-K	Director or officer change; Other events
2026-08-11	PRE 14A	Proxy statement
2026-07-01	13G/A	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 06:11 AM UTC. Small caps move fast; check the latest filings.